Abstract Inflammation in the brain is a prominent feature in Alzheimer's disease (AD). Recent studies suggest that chronic inflammation can be a consequence of failure to resolve the inflammation. Resolution of inflammation is mediated by a family of lipid mediators (LMs), and the levels of these specialized pro-resolving mediators (SPMs) are reduced in the hippocampus of those with AD. In the present study, we combined analysis of LMs in the entorhinal cortex (ENT) from AD patients with in vitro analysis of their direct effects on neurons and microglia. We probed ENT, an area affected early in AD pathogenesis, by liquid chromatography-tandem mass spectrometry (LC-MS-MS), and found that the levels of the SPMs maresin 1 (MaR1), protectin D1 (PD1), and resolvin (Rv) D5, were lower in ENT of AD patients as compared to age-matched controls, while levels of the pro-inflammatory prostaglandin D 2 (PGD 2 ) were higher in AD. In vitro studies showed that lipoxin A 4 (LXA 4 ), MaR1, resolvin D1 (RvD1), and protectin DX (PDX) exerted neuroprotective activity, and that MaR1 and RvD1 down-regulated β-amyloid (Aβ) 42 -induced inflammation in human microglia. MaR1 exerted a stimulatory effect on microglial uptake of Aβ 42 . Our findings give further evidence for a disturbance of the resolution pathway in AD, and indicate that stimulating this pathway is a promising treatment strategy for AD.
Introduction
Lipids represent the primary structural component of the cell membrane and represent up to 50 % of the brain dry weight. Lipid dysregulation has been found in Alzheimer's disease (AD) [1] [2] [3] , the most common type of dementia. In the AD brain, lower levels of the omega (ω)-3 fatty acid (FA) docosahexaenoic acid (DHA) were reported [4] . In elderly persons, a correlation between higher plasma levels of ω-3 FAs and less cognitive decline has been shown [5] . Prostaglandins (PGs) and leukotrienes (LTs) are classical proinflammatory lipid mediators (LMs) that mediate fever and pain. PGs and LTs are biosynthesized from arachidonic acid (AA) via cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) pathways, the activity of which have been shown to be elevated in AD [6, 7] . Suppression of these pathways by inhibition or gene depletion of COX or 5-LOX successfully reduced AD-like pathologies in AD animal models [8] .
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The elevated levels of pro-inflammatory LMs are in line with abundant evidence of the inflammatory process in the AD brain [9] [10] [11] , characterized by activated microglia, astrocyte proliferation, and an increased production of other inflammatory factors such as cytokines. The major histopathological hallmarks of AD include amyloid plaques mainly composed of aggregated β-amyloid (Aβ) peptide [12] , neurofibrillary tangles (NFTs) consisting of hyper-phosphorylated tau protein [13] , and loss of neurons [12] . Aβ has been shown to induce neurotoxicity [14] and to activate microglia, upon which they secrete pro-inflammatory mediators that can also cause neurotoxicity [15] . Notably, the production of Aβ is increased by inflammation [16] , indicating the existence of a vicious circle of reciprocal stimulation in AD [15] . Moreover, an early epidemiological study suggested a lower prevalence of dementia in patients on long-term treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) [17] .
Recent studies have highlighted a role of LMs, not only in stimulating inflammation but also in stimulating its resolution, i.e., termination of inflammation and restoration of the inflamed tissue. In resolution, a novel group of LMs termed specialized pro-resolving lipid mediators (SPMs) plays an important role. SPMs are biosynthesized from ω-3 and ω-6 FAs by the activities of lipoxygenases (LOXs) and COXs [18] . Hence, there is a duality of these enzymes with regard to producing pro-inflammatory and pro-resolving LMs. Several series of SPMs have been identified: lipoxins (LXs) derived from AA [19] , E-series resolvins (RvEs) derived from eicosapentaenoic acid (EPA) [20] , and D-series resolvins (RvDs), protectin/neuroprotectin (PD/NPD), and maresins (MaRs) derived from DHA [21, 22] . SPMs have potent proresolving actions, leading to cessation of immune cell infiltration, down-regulation of pro-inflammatory and up-regulation of anti-inflammatory mediators, and promotion of phagocytosis and of tissue regeneration [23] [24] [25] [26] . Altogether, these activities promote the return to homeostasis. Resolution of inflammation is thus an actively controlled process, mediated by SPMs, rather than a passive dissipation of the inflammatory response due to cessation of activating stimuli [18] .
The inflammatory response is a defense mechanism of the body to eliminate harmful stimuli, hence protective, and should be naturally ended or resolved upon successful elimination. However, if left uncontrolled, inflammation may persist and result in chronic inflammation. Interventions based on inhibition of inflammation in AD patients have in most cases not been successful [27] . In addition, long-term use of NSAIDs may induce gastrointestinal and cardiovascular side effects [28] . Therefore, there is call for a novel strategy, not based on classical anti-inflammatory treatment, and therapeutic strategies based on resolving the inflammatory state in AD are therefore of interest. The inflammatory response would thereby be induced to progress to its natural end, promoting the beneficial and restorative aspects of inflammation, which may be lost in anti-inflammatory treatments. In a recent study, we characterized the resolution pathway in the hippocampus region of AD patients, and found altered levels of SPMs, their receptors, and of an enzyme involved in their synthesis [29] . In the present study, the aim was to investigate a wider spectrum of LMs, with a special focus on SPMs, using the liquid chromatography-tandem mass spectrometry (LC-MS-MS) based approach in postmortem tissue samples of entorhinal cortex (ENT), a brain region of importance for memory and affected early in AD pathogenesis [30] . To further understand the role of SPMs in the brain, and to evaluate the therapeutic potential, we also analyzed their actions in vitro on neuronal survival and microglial function.
Methods

Postmortem Human Brain Samples
Postmortem tissue samples from the ENT were obtained from seven subjects with neuropathologically confirmed AD (Braak stage 5-6/definite AD), and seven non-demented control subjects, all from the Brain Bank at Karolinska Institutet. All AD patients were clinically diagnosed and confirmed by pathological examination. None of the control subjects had significant pathological changes in the brain consistent with AD neuropathology. The age of the subjects at the time of death, and the postmortem interval, did not differ significantly between the AD and control groups (see Table 1 for patient information). As part of the clinical routines, the apolipoprotein E (ApoE) genotype was analyzed, and information on carriers of one or two E4 alleles is included in Table 1 . The ENT tissue was dissected from the frontal pole of the temporal lobe on dry ice and kept at −80°C until further processing.
Lipid Mediator Metabololipidomics
For LM extraction, human ENT tissues were thawed on ice, weighed, and then gently homogenized by a glass dounce. Internal deuterium-labeled standards d 4 -LTB 4 , d 5 -LXA 4 , d 5 -RvD2, and d 4 -PGE 2 (500 pg each) in 2 ml of ice-cold methanol were added to each sample, in order to facilitate quantification and sample recovery. Next, the samples were kept at −20°C for 45 min for protein precipitation, and were then centrifuged at 1200×g (4°C for 10 min). Supernatants were collected and brought to less than 1 ml of methanol content with nitrogen gas. An automated extraction system (Rapid Trace, Biotage, NC, USA) was used to extract the samples as in [31, 32] . Briefly, acidified samples (pH 3.5 by HCl) were rapidly loaded onto solid-phase C18 cartridges, preconditioned with 3 ml methanol and 6 ml H 2 O, and then washed with 4 ml H 2 O and 5 ml hexane. The products were eluted with 9 ml methyl formate, and then brought to dryness with nitrogen gas. The dried products were immediately suspended in methanol-water (50:50 vol/vol) for LC-MS-MS automated injections.
The LC-MS-MS system included a LC-20AD HPLC and a SIL-20AC auto-injector (Shimadzu, Kyoto, Japan), paired with a QTrap 6500 (ABSciex, CA, USA). LMs were eluted through an Eclipse Plus C18 column (100 mm×4.6 mm× 1.8 μm; Agilent, CA, USA). A mobile phase of methanolwater-acetic acid of 55:45:0.01 (vol/vol/vol) was ramped to 85:15:0.01 over 10 min, and then to 98:2:0.01 for the next 8 min. This was subsequently maintained at 98:2:0.01 for 2 min. The flow rate was 0.4 ml/min. The QTrap 6500 was operated in negative ionization mode. Scheduled multiple reaction monitoring (MRM) with a 90 s window was coupled with information-dependent acquisition (IDA) and an enhanced product ion scan (EPI) [31, 32] . Each LM parameter was optimized individually.
Each LM was monitored by recently published criteria [31, 32] , including matching retention time to synthetic and authentic materials, and at least six diagnostic ions for each LM. Linear calibration curve with r 2 value of 0.98-0.99 was obtained for each LM using authentic compound mixtures and deuterium-labeled LM at 0.78, 1.56, 3.12, 6.25, 12.5, 25, 50, 100, and 200 pg.
Cell Cultures
Human SH-SY5Y Neuroblastoma Cells SH-SY5Y neuroblastoma cells (ATCC, Sweden) were cultured in DMEM/F12 medium supplemented with Glutamax™ (Life Technologies, Stockholm, Sweden), supplemented with 10 % heat-inactivated fetal calf serum (FCS) (Life Technologies, Stockholm, Sweden), at 37°C in humidified air containing 5 % CO 2 . The cells were sub-cultured at 80 % confluence. Differentiated SH-SY5Y cells have been reported previously as a model of human neuron-like cells, which have morphological and biochemical similarity to primary neurons [33] . SH-SY5Y cells were differentiated with 10 μM retinoic acid (RA) (Sigma, Stockholm, Sweden) in complete medium for 5 days. Subsequently, the cells were harvested with enzymefree cell dissociation buffer (Life Technologies, Stockholm, Sweden), and re-seeded at a density of 20,000 cells/well in 48-well plates coated with Matrigel reduced of growth factors (Becton Dickinson, USA). After allowing the cells to attach for 1 day, the culture medium was replaced with serum-free medium containing brain-derived neurotrophic factor (BDNF) (Life Technologies, Stockholm, Sweden) at a final concentration of 25 ng/ml. Experiments were performed after 5 days of differentiation in this medium. All treatments were prepared in fresh serum-free DMEM/F12 medium supplemented with Glutamax™.
Human CHME3 Microglial Cells
Human microglial cells (CHME3) were kindly provided by Prof. M Tardieu, Neurologie pédiatrique, Hôpital Bicêtre, Hôpitaux de Paris, Paris, France. CHME3 cells were cultured in DMEM/high glucose medium (Life Technologies, Stockholm, Sweden) supplemented with Glutamax™ (Life Technologies, Stockholm, Sweden) and 10 % FCS. The culture medium was changed twice per week, and the cells were sub-cultured at 80 % confluence, and seeded into 6-well plates for experiments.
Immunocytochemistry
Differentiated SH-SY5Y cells and CHME3 microglia cells cultured on coverslips were fixed and processed for immunocytochemistry. The cells were fixed with 4 % paraformaldehyde for 20 min at room temperature (RT), washed with phosphate-buffered saline (PBS) for 3×10 min, blocked with 5 % normal goat serum for 45 min at RT, and incubated over night at 4°C with primary antibodies. Neuroblastoma cells were stained with antibodies to G protein-coupled receptor 32 (GPR32), and microglia were stained with antibodies to GPR32 and lipoxin A 4 (LXA 4 ) receptor/formyl peptide receptor 2 (ALX/FPR2). Both antibodies were diluted 1:100 in PBS containing 5 % normal goat serum and 0.1 % Triton-X100. After washing with PBS for 3×10 min, the coverslips were incubated for 2 h at RT with FITC-conjugated goat anti-rabbit IgG diluted 1:200 in PBS containing 5 % normal goat serum. The coverslips were then washed with PBS for 3×10 min, mounted with fluorescence mounting medium (DAKO Sweden AB, Stockholm, Sweden), and analyzed in a Nikon E800 microscope.
Western Blot
Analysis of ALX/FPR2 and GPR32 by Western blotting was performed on differentiated SH-SY5Y cells and CHME3 microglia cells lysed with radio-immunoprecipitation assay (RIPA) buffer, supplemented with 1 % protease inhibitor cocktail (Sigma-Aldrich, Stockholm, Sweden) and 1 % phosphatase inhibitor cocktail (Thermo scientific, Stockholm, Sweden), and centrifuged at 11,000 rpm at 4°C for 20 min. The supernatant was collected and total protein concentration determined by a BCA assay kit (Thermo scientific, Stockholm, Sweden). Briefly, samples containing 40 μg protein each were mixed with equal volume of 2X Laemmli sample buffer (Thermo scientific, Stockholm, Sweden), and were boiled at 95°C for 5 min. The denatured samples were then loaded on a 10 % SDS-PAGE gel, after which the proteins were transferred to a nitrocellulose membrane under 85 mA current over night at 4°C. The membranes were blocked with 5 % non-fatty dry milk at room temperature for 45 min, and incubated with primary antibodies diluted (1:500 for anti-GPR32 and 1:1000 for anti-ALX/FPR2 antibodies) in Trisbuffered saline with 0.1 % Tween20 (TBS-T) at 4°C over night. The binding of primary antibodies was probed with horseradish peroxidase (HRP)-conjugated secondary antibodies (GE healthcare, Stockholm, Sweden) diluted (1:1000) in TBS-T, followed by incubation with enzymatic chemiluminescence (ECL™ Prime, GE healthcare, Stockholm, Sweden) reagent for 5 min. A CCD camera (LAS-3000 luminescence image analyser, Fuji Film, Tokyo, Japan) was used to detect the signals.
Cell Stimulation
SH-SY5Y Cell Stimulation
To analyze the effect of SPMs on neuronal survival, apoptosis was induced by incubating the differentiated SH-SY5Y cells with 100 nM staurosporine (STS) (Sigma, Stockholm, Sweden). The SPMs maresin 1 (MaR1), LXA 4 , resolvin D1 (RvD1), and protectin DX (PDX) (all from Cayman Chemical, MI, USA), at 0-0.5 μM, were added to the cultures immediately prior to addition of STS. The treatment with SPMs was repeated by addition to the cultures at 6 and 24 h, and viability and cell death were analyzed at 48 h. The effects of SPMs alone in the absence of STS were also analyzed.
CHME3 Cell Stimulation
To assess the effect of SPMs on phagocytosis of Aβ 42 , CHME3 cells were seeded into 6-well plates (100,000 cells/ well), and incubated with 1 μg/ml HiLight488-conjugated Aβ 42 (Anaspec, Fremont, USA) together with a range of concentrations (0-100 nM) of SPMs for 1 and 6 h. Phagocytosis of Aβ 42 was analyzed by flow-cytometry.
To analyze the effects of SPMs on Aβ 42 -induced microglia activation, CHME3 cells were seeded into 6-well plates and stimulated with 10 μg/ml Aβ 42 combined with 0-0.5 μM SPMs for 1 and 6 h, and the cells were harvested at the end of the experiment for flow-cytometry analysis. To analyze the effects of MaR1 on microglial phenotype at basal unstimulated conditions, the CHME3 cells were seeded into 6-well plates and stimulated with 0-1 μM MaR1. After 6 h incubation, the cells were harvested for flow-cytometry analysis.
Assessment of Cell Death and Viability
Cell death was assessed by lactate dehydrogenase (LDH) assay. A sample of 100 μl cell culture supernatant was transferred to a 96-well plate and incubated with LDH reagent (Roche, Stockholm, Sweden) for 30 min, after which the absorbance was measured at 340 nm. Cells lysed with 10 % Triton X100 to induce 100 % cell death served as positive control (PC). The absorbance of the medium from the other wells in the experiment was normalized to the PC. Cell viability was assessed by incubating the remaining cells for 2 h at 37°C with resazurin salt (Sigma, Stockholm, Sweden) at a final concentration of 0.01 % in culture medium, after which the fluorescence intensity was analyzed at 590 nm. The fluorescence signal of the medium from the vehicle treatment served as control, and the signal measured in the other wells in the experiment was normalized to this control signal.
Flow-Cytometry
For analysis of membrane-associated cellular markers, the cells were harvested as described previously [34] and fixed with 1 % paraformaldehyde in PBS at room temperature for 45 min. The cells were washed once by adding 5 ml PBS, centrifuged at 400×g for 10 min, and then resuspended with 1 % bovine serum albumin (BSA, Sigma-Aldrich, Stockholm, Sweden) in PBS. Cell suspensions were incubated for 45 min on ice with fluorophore-conjugated antibodies against CD40, CD86, CD11b, CD33, CD163, CD206, and CD80, major histocompatibility complex class II (MHC-II), at their respective working concentration (see Table 2 ). The cells were then washed once by adding 1 ml PBS and centrifuged at 500×g for 5 min, resuspended in 200 μl 1 % BSA, and analyzed in a FACS Calibur cytometer (Becton Dickinson, USA). The proportion of microglia positive for each cell surface marker was assessed by determining the percentage of cells showing a signal in the proper channel exceeding the signal of the isotype control. All flow-cytometric data were analyzed in Cell Quest Pro software.
Statistical Analysis
Statistical analysis was performed in Statistica 12 (Dell Software, Aliso Viejo, USA), and SPSS software (version 21.0, IBM Corporation, NY, USA). Pairwise comparison between treatments/groups was analyzed by Mann-Whitney U test. All data from the in vitro experiments were normalized to the average of each individual experiment. Variance was analyzed by the Kruskal-Wallis test, and the post hoc test built into the Kruskal-Wallis analysis in Statistica 12 was used for group comparisons. P<0.05 was considered statistically significant.
Study Approval
The use of human postmortem brain samples was approved by the Ethical committee at Karolinska Institutet (ethical permit number 2011/680-31/1).
Results
Identification and Quantification of SPMs in the Human Entorhinal Cortex
LC-MS-MS-based profiling was used to analyze LMs in the ENT from both AD patients and controls. Representative multiple reaction monitoring (MRM) profiles in control and AD ENT tissue are shown in Fig. 1a , along with MS-MS spectra employed for identification (Fig. 1b) . The LMs were quantified by the targeted MRM method using specific ion pairs including the parent ion (Q1) and the diagnostic daughter ion (Q3). Previously, we have shown the occurrence of LXA 4 , RvD1, and MaR1 in the human hippocampus [29] , and we present here evidence for the presence in the human brain of the SPMs RvE1, RvE2, RvD2, and RvD5, as well as other LMs (see Fig. 1 and Table 3 ). Comparisons between ENT from AD patients and controls did not reveal any difference with regard to LXs derived from AA (Table 3) . However, levels of RvD5, MaR1, and protectin D1 (PD1), all derived from DHA, were lower in the AD group than in the control group (Fig. 2a-c) , whereas no apparent differences were observed with regard to RvD1 and RvD2 (Table 3) .
In the EPA bioactive metabolome, the ENT levels of RvE1 and RvE2 did not differ between AD and controls ( Table 3) . The levels of pro-inflammatory LMs, including LTB 4 , 20-OH-LTB 4 , dihydroxyeicosatetraenoic acid (diHETE), PGE 2 , PGF 2α , and thromboxane (Tx) B 2 , did not differ between the AD and control group, except for significantly higher levels of prostaglandin D 2 (PGD 2 ) in AD patients (Table 3 and Fig. 2d ).
Among the subjects included in this study, six of the AD patients had one or two ApoE4 alleles and three of the controls (see Table 1 ). There was no correlation between ApoE4 genotype and the levels of SPMs (data not shown).
Actions of SPMs on STS-Induced Neuronal Apoptosis
In view of the reduced levels of SPMs in the AD brain, we further analyzed their direct effects on neurons with regard to potential protective or rescuing actions. A model of STS-induced neuronal apoptosis in differentiated neuroblastoma cells was used. Incubation of the cells with 100 nM STS resulted in significantly reduced cell viability and increased cell death as determined by resazurin (Fig. 3a) and LDH (Fig. 3b) assay, respectively. The cell survival, as defined by the ratio between data from the resazurin and LDH assays, was significantly decreased (Fig. 3c) . These parameters were also used to assess the effects of LXA 4 , RvD1, MaR1, and PDX, in the STS-model. Treatment with LXA 4 at (Fig. 4a) , whereas no effect was seen with MaR1. Neuronal cell death induced by STS was significantly reduced by RvD1 at 0.005 and 0.5 μM, by 0.05 and 0.5 μM MaR1, and by 0.005 and 0.05 μM PDX (Fig. 4b) . No effect on cell death was observed after incubation with LXA 4 . The STS-induced decrease in cell survival (as defined by the ratio between data from resazurin and LDH assays) was significantly counteracted by 0.5 μM LXA 4 , by 0.005 and 0.5 μM RvD1, and by 0.05 μM MaR1, along with a significant protection also by PDX at 0.05 and 0.5 μM (Fig. 4c) .
The differentiated neuroblastoma cells were also incubated with the LMs at basal conditions, and an increase in cell survival (as defined by the ratio between data from resazurin and LDH assays) was observed with 0.5 μM LXA 4 and 0.005 μM RvD1 (see Supplementary Fig. S1a-c) .
Actions of SPMs on Microglial Activation Induced by Aβ 42
Microglia represent the brain equivalent of monocytes/ macrophages in the periphery, and SPMs have potent actions on these peripheral cells. In view of this, and the fact that microglial activation is observed in the AD brain, we used a model of human microglia incubated with Aβ 42 , known to activate microglia, to investigate potential actions of SPMs. Incubation of the human CHME3 microglial cells with 10 μg/ml Aβ 42 resulted in upregulation of the levels of CD11b after 1 and 6 h incubation (Fig. 5a, b) , as well as of the CD40 expression at 6 h (Fig. 5c ). Aβ 42 did not induce any significant change in CD163, CD206, CD200R, and CD33 (data not shown). Incubation of the microglia with various concentrations of RvD1 and MaR1 for 1 h (Fig. 5a) , and with RvD1 for 6 h (Fig. 5b) , resulted in a decrease in the Aβ 42 - (Fig. 5c) .
Actions of SPMs on Microglial Phagocytosis of Aβ 42
SPMs are known to stimulate non-phlogistic phagocytosis, and stimulating microglial phagocytosis of Aβ could conceivably be of benefit in AD. In order to investigate the effects of SPMs on phagocytosis of Aβ 42 , the human microglial cells (CHME3) were co-incubated with 0-100 nM SPMs and 1 μg/ ml Hilight-488-conjugated Aβ 42 for 1 and 6 h. Quantification by flow-cytometry showed that MaR1 increased the phagocytosis of fluorophore-conjugated Aβ 42 at 100 nM after 1 and 6 h incubation, and after 6 h, there was an increase also by 1 nM MaR1 (Fig. 6) . Kruskal-Wallis analysis showed a treatment effect at both 1 and 6 h (Fig. 6 ). There was no significant effect on Aβ 42 phagocytosis by LXA 4 , RvD1, or PDX (data not shown).
Actions of MaR1 on Microglial Phenotype
In view of the action of MaR1 on Aβ 42 phagocytosis, as well as the deficiency of MaR1 in AD ENT, and hippocampus [29] , the phenotype of the microglial cells upon MaR1 treatment was given special attention. A panel of interest, including the pro-(CD11b activated, CD86, CD40, CD80, MHC-II) and antiinflammatory (CD163, CD206) markers, was used in the assessment, as well as CD33, a member of the Siglec family of lectins involved in endocytosis. The CHME3 microglia were stimulated with 0-1000 nM MaR1 for 1 and 6 h, after which the effects on the markers were assessed by flow-cytometry.
The treatment with MaR1 significantly decreased the levels of the pro-inflammatory markers CD11b activated, MHC-II and CD86 (Fig. 7b-e) , as well as the levels of CD33 (Fig. 7a) . The levels of the anti-inflammatory markers CD163 and CD206 remained unchanged upon incubation with MaR1 (data not shown).
SPM Receptors
Only some of the receptors for SPMs have been determined so far, i.e., ALX/FPR2 and GPR32, both of which are receptors for LXA 4 and RvD1, ChemR23, receptor for RvE1, and BLT1 or LTB 4 R, receptor for LTB 4 and RvE1. However, to our knowledge, the receptors for MaR1 and NPD1 have not been described. In the sections above, we present evidence for direct effects of SPMs, including LXA 4 and RvD1, on differentiated neuroblastoma cells and on microglial cells, and immunocytochemical analysis demonstrates the occurrence of GPR32 in the neurons (Fig. 8a) , and of both GPR32 and (Fig. 8b, c) . The staining was validated by Western blot analysis (Fig. 8a-c) .
Discussion
Chronic inflammation, a characteristic of the pathology in the AD brain [35, 36] , could be a consequence of failure in resolution of inflammation. The existence of a dysregulated resolution mechanism in the AD brain is indicated by previous reports on decreased levels of PD1 [4, 29] and MaR1 [29] in AD hippocampus, and reduced levels of LXA 4 in the hippocampus and CSF of AD patients [29] . This opens up for a possible treatment strategy based on replacement of proresolving LMs and/or stimulation of pro-resolving activities. A prerequisite for this is an understanding of the actions of SPMs on brain cells, as well as to investigate whether their reduction is common to other brain regions. In the present study, we combined these aspects by studies on the effects of SPMs on neurons and microglia (see below), and LC-MS-MS analysis of lipids in the ENT, a region that plays an important role in declarative memory, particularly spatial memory formation, and that is affected at an early stage of AD pathogenesis [30] . The LC-MS-MS analysis provided further evidence for a dysregulation of resolution. The analysis identified D-and E-series resolvins, maresins, protectins, and AA-derived lipoxins in the human ENT. To our knowledge, neither RvD2 and RvD5 nor RvE1 and RvE2 have been shown so far in the human brain. Consistent with the earlier findings in the hippocampus [4, 29] , the levels of MaR1 and The observed alterations in the hippocampus and ENT, as well as in the CSF [29] , indicate that a LM profile, with an emphasis on reduction in SPMs, appears as a common feature in AD pathology, and may therefore be involved in development of AD-related neurodegeneration. However, the findings were not completely equivalent. In contrast to the findings in the hippocampus, the levels of LXA 4 in the ENT did not differ between AD patients and controls, indicating a regional difference. Similarly to the hippocampus [29] , the ENT had higher levels of the pro-inflammatory LM PGD 2 in AD patients. PGD 2 is produced by hematopoietic PGD synthase (HPGDS), an enzyme increased in glial cells within senile plaques in AD brains [7] . Clinical trials where human AD patients are given SPMs to correct a deficiency in the levels of SPMs have not yet been performed. However, results from a clinical trial on AD patients treated with the SPM-precursors DHA and EPA showed a positive effect on cognition compared to placebo in a subgroup of AD patients having less severe cognitive decline (mini-mental state examination, MMSE>27) [37] . So far, only a few studies have analyzed the cellular origin of SPMs in the brain. In vitro studies demonstrated the production of PD1 in mixed human neuron-glia cell cultures [4] , and our studies on the human microglia cell line (CHME3) showed LXA 4 and RvD1 in the conditioned medium [38] . Immunohistochemical studies on human and murine brains have shown the occurrence of the biosynthetic enzymes 5-LOX and 15-LOX in neurons and glia [6, [39] [40] [41] [42] . Substrates for these enzymes are poly-unsaturated FAs (PUFAs) within the cellular membranes, DHA being the most abundant FA in the human brain. Altogether, this supports a local production of SPMs by neurons and glia in the brain. Earlier studies have shown higher levels of 5-LOX [8] and 12/15-LOX [42] in AD brains vs. controls, which may indicate an increased capacity to produce SPMs, and a contradiction to the reduced levels observed for SPMs. However, the LOX enzymes are also able to produce pro-inflammatory LMs, including LTs. Studies by Praticò showed that the presence of 12/15-LOX was accompanied by higher levels of IL-12P40, a pro-inflammatory cytokine and lack of this enzyme correlated with protection against oxidative stress [42] . Under certain conditions, the production of pro-inflammatory LMs can be switched to the production of pro-resolving LMs, a process termed Bclassswitching^ [43, 44] . Hence, the production profile of the enzymatic pathway producing LMs appears to be Bprogrammable^by the conditions in the tissue. Without knowledge on which production profile that is active in the brain, the consequences of altered levels are hard to foresee. The mechanisms behind class-switching are still not fully known. Cholinergic signaling through α7 nicotinic acetylcholine receptor (α7nAChR) has been suggested to stimulate a shift to pro-resolving LM production [45] . The deficiency in cholinergic signaling in the AD brain is well known. In a recent study on human microglia, we showed that inflammation induced by Aβ 42 produced changes in resolution mechanisms, including the levels of α7nAChR, suggesting that inflammation caused by Aβ 42 may be more difficult to resolve compared to the inflammation caused by a classical infectious stimulus such as lipopolysaccharide (LPS) [38] . Furthermore, the substrates for SPM biosynthesis, PUFAs, are reduced in the AD brain (see [46] ), and also the enzymatic machinery in the liver for production of PUFAs from dietary sources of substrates such as α-linoleic acid is compromised in AD patients [47] . A failure in class-switching mechanisms may thus prevent an increased production in SPMs in spite of higher levels of LOXs.
In order to better understand the consequences of a deficiency in the levels of SPMs with regard to neuronal cell death and overabundance of Aβ 42 , conditions intimately associated with AD, we performed in vitro experiments on monocultures of human neuronal and microglial cells. We found that all SPMs tested (LXA 4 , MaR1, PDX, and RvD1) showed some degree of protection against neuronal cell death induced by STS. Furthermore, MaR1 had pronounced pro-resolving immunomodulatory effects on microglia, by stimulating phagocytosis of Aβ 42 and downregulating pro-inflammatory markers. By connecting these pre-clinical data to the deficiencies in the levels of SPMs in the AD brain shown in the present study, as well as in previous studies on the hippocampus [4, 29] , we hypothesize that a deficiency in the levels of SPMs, particularly of MaR1, deprives the brain of protective and restorative signals which can contribute to the pathogenesis in AD. In addition to the present study, beneficial actions of SPMs have been shown in in vitro and in vivo models related to AD, including reduction of Aβ pathology and inflammation, and an improvement in cognitive function [4, [48] [49] [50] . However, few studies have in- require the presence of receptors for SPMs on the responding cells. RvD1 and LXA 4 bind to the same receptor, ALX/FPR2, and RvD1 can also bind to GPR32 [51, 52] . Receptors for MaR1, PD1, or PDX have not yet been described. We have shown the occurrence of ChemR23, a receptor for RvE1, and ALX/FPR2 in both neurons and glia in the human brain [29] , as well as of ALX/FPR2 and GPR32 in the human microglial cell line analyzed in the present study [38] , complemented here by immunocytochemical evidence. In the present study, we also show the occurrence of GPR32 in the differentiated neuroblastoma cells used as a neuronal model, indicating that they can receive protective signals through this receptor. The signaling events downstream of receptors mediating pro-resolving effects of SPMs are not yet fully characterized. STS targets mitochondria and induces oxidative stress [53] , which has been described to be associated with neuronal loss in AD (see, e.g., [54] ). The present results may therefore indicate that neuroprotection offered by SPMs is mediated at least in part via a mitochondrial pathway. This is in line with a study on murine and human macrophages in which pre-treatment with LXA 4 diminished STS-induced apoptosis by promoting the PI3K/Akt and ERK/ Nrf-2 pathway, and preserving mitochondrial function and integrity [55] . Reduction in oxidative stress has been shown to be involved in the protective effect of PD1 in in vitro models of neurodegeneration [56, 57] . PDX, used in the present study, is an endogenous isomer of PD1, and differs from PD1 with regard to its biosynthetic route, chemical structure, and potency [58] . PDX is less potent in inducing resolution of inflammation compared to PD1 [59] , but has been shown to inhibit platelet aggregation via inhibition of COX-1 at nanomolar concentrations, an action that is absent for PD1 [60] . PD1 was shown to protect retinal and neuronal cells through an increase in the antiapoptotic Bcl-2 family, decreasing pro-apoptotic Bax and Bad expression, thus inhibiting caspase-3 activation [4, 61, 62] and stimulating the PI3K/Akt and mTOR/p70S6K pathways, which are supportive for cell survival [63] . It is currently not known to which degree the effects of PDX on intracellular signaling resemble those described for PD1, but the molecular similarity and the protective effects they share suggest that effects on anti-and pro-apoptotic proteins and PI3K/Akt mediate the neuroprotection by PDX. Peroxisome proliferatorassociated receptor (PPAR)-γ is a receptor for several different FAs and LMs, including LXA 4 [64] and RvD1 [65] , as well as PD1, which was shown to exert neuroprotection via induction of neuronal PPAR-γ [50] . There are no published data available on the effects of MaR1 on PPAR-γ, although it is likely that MaR1, being similar in structure to PD1 and RvD1, can bind to PPAR-γ and explain its neuroprotective effect. Aβ 42 induces a predominantly pro-inflammatory phenotype in microglia [38, 60, 66] . It has previously been shown that Aβ 42 stimulates the expression of cellular activation markers such as CD40 [67] , and this effect was replicated in our model of human microglia. The increase in CD40 was significantly diminished when MaR1 or RvD1 were added to the cultures, while LXA 4 and PDX were ineffective in this regard. The activity of the JAK1/2-STAT1 pathway is known to increase the expression of CD40, and inhibition of this pathway by lovastatin was shown to decrease CD40 in mouse microglia [68] . Although no studies have investigated whether SPMs have inhibitory effects on the JAK/STAT pathway, it is a potential mode of anti-inflammatory action for SPMs. The levels of CD40 is of particular importance in AD since it is increased in the AD brain [69] , and when binding to its ligand CD40L it promotes neuronal cell death [70] , and stimulates production of Aβ [71] . CD11b interacts with CD18 and forms a heterodimer, macrophage antigen complex (Mac)-1, which is an integrin receptor present on eosinophils, neutrophils, monocytes, macrophages, and microglia. Although it is mostly known for its role in adhesion of activated blood borne cells, Mac-1 has also been shown to be involved in microglial migration, phagocytosis, and inflammation [72] . Upon activation, CD11b undergoes a change that causes hyperadhesion [73] . We show in the present study for the first time that activation of CD11b occurs in microglia exposed to Aβ 42 , and that MaR1 diminished this activation. Hyperadhesion is a consequence of activation in eosinophils [73] , and neutrophils [74] , and it is reasonable to assume that this is also true in microglia. Activation of CD11b also occurs in macrophages [75] , where it is related to opsonic complement-dependent phagocytosis, and a similar modulatory effect on microglial phagocytosis is possible. The transcription of proinflammatory genes after activation of nuclear factor (NF)-κB and activator protein (AP)-1 is well-known and fundamental events in pro-inflammatory activation. PD1 and RvD1 have been shown to inhibit activation of NF-κB [65, 76] . Inhibition by RvD1 was shown to be dependent on PPAR-γ [65] . LXA 4 was shown to inhibit the activation of both NF-κB and AP-1 [76] . Activation of mitogen-activated protein kinases (MAPK) by phosphorylation is another well-known event in pro-inflammatory activation upstream of NF-κB activation, and we have previously shown an increase in the phosphorylation of c-jun n-terminal kinase (JNK) and p38 upon exposure of CHME3 microglia to Aβ 42 [38] . Therefore, it is likely that inhibition of MAPK phosphorylation contributes to the anti-inflammatory effects of SPMs. Support for this has been provided in a mouse model of traumatic brain injury (TBI) [77] , where LXA 4 decreased TBI-induced phosphorylation of JNK, and in a study on human macrophages, where MaR1 and RvD1 decreased zymosaninduced phosphorylation of JNK and p38, in parallel with inhibition of NF-κB activation [78] . Furthermore, activation of PPAR-γ has been shown to exert an antiinflammatory effect on microglia in several studies [79] [80] [81] , and in view of the ability of several SPMs to act as ligand for PPAR-γ, it is a likely mediator of their anti-inflammatory effects.
In a previous study, we showed an increase in Aβ 42 phagocytosis upon stimulation of human CHME3 microglia with DHA and EPA, precursors for SPMs [34] . Conceivably, this effect may be indirect through conversion to SPMs, for which these cells express the relevant machinery [38] . The data in the present study showed that the DHA-derivative MaR1, but not RvD1 or PDX, or the AA-derived LXA 4 , increased the phagocytosis of Aβ 42 , suggesting that MaR1 has a distinct role in microglia-mediated removal of Aβ. RvD1 has been reported previously to increase phagocytosis of the fibrillar form of Aβ 42 by peripheral blood mononuclear cells (PBMCs) from AD patients [49] . However, this effect was not observed in the present study on CHME3 microglia, indicating different actions of SPMs in the periphery vs. the brain.
The prominence of MaR1 in stimulating phagocytosis as well as neuroprotection motivated further investigation. Consistent with the increased Aβ 42 phagocytosis, we found that MaR1 significantly down-regulated the levels of CD33, a 67-kDa trans-membrane glycoprotein expressed by microglia, also shown to be elevated in AD, and associated with decreased cognitive function [82] . Studies by Griciuc et al. showed that CD33 inhibits microglial uptake and clearance of Aβ 42 [83] . In addition to cytoprotection, and the inhibitory effects on inflammatory markers, PPAR-γ has been shown in several studies to be a positive regulator of phagocytosis [84] [85] [86] . Similarly to the discussion on neuroprotection, it can be hypothesized that MaR1 exerts its stimulatory effects on phagocytosis by binding to PPAR-γ. We also tested the effects of MaR1 on an extended set of pro-and antiinflammatory markers, and found that the levels of CD80, CD86, CD11b, and MHC-II were decreased by incubation with MaR1. This finding is in line with an earlier study, in which an increase in the production of MaR1 was associated with decreased levels of the pro-inflammatory markers CD54 and CD80 in interferon (IFN)-γ-and LPS-stimulated macrophages, as well as with increased levels of the antiinflammatory phenotype markers CD163 and CD206 [87] .
Except for MaR1, for which data have not been presented so far, it appears that PPAR-γ is a mechanism in common for SPMs contributing to their cytoprotective and antiinflammatory effects, as well as the stimulation of phagocytosis. It is reasonable to assume that the response of a cell is an outcome of the activation of PPAR-γ together with other additional signaling pathways. A tentative hypothesis is that binding of SPMs to membrane receptors such as GPR32 modulates the effects elicited by the activation of genes that follow the concurrent binding of SPMs to PPAR-γ into a protective and anti-inflammatory cellular (i.e., pro-resolving) response.
In conclusion, our results further strengthen the argument that there is a deficiency in the resolution of inflammation in the AD brain, and extend our previous findings to the ENT and in vitro mechanistic studies. In particular, the DHAderivative MaR1 is consistently lower in AD. Our in vitro data showed an important role of MaR1 in maintaining homeostasis in the brain by promoting neuronal survival, microglial removal of Aβ 42 , and limiting microglial inflammation. Therefore, reduced levels of MaR1 and other SPMs may play an important role in the pathogenesis of AD, by resulting in decreased restorative and protective activities, as well as by perpetuating inflammation in the AD brain. Our results also indicate that restoring this deficiency by treatment with SPMs or analogues thereof is a promising treatment strategy for AD.
